High-throughput screening (HTS) allows scientists to test thousands of samples at once. These samples can be of a wide variety, and include, but are not limited to, amino acids, chemical compounds or cells.
Orbit Discovery Ltd., (“Orbit”) a privately held biopharmaceutical company focused on discovering candidate peptide therapeutics harnessing proprietary affinity and cell-based functional screening platforms, has been awarded a Smart grant by Innovate UK, the UK’s innovation agency.
First neurodegenerative disease model launched from bit.bio's new ioDisease Model portfolio.
Dotphoton, an industry-leading raw image compression company and Hamamatsu Photonics, a world leader in optical systems and photonics manufacturing, are pleased to announce their new partnership.
Researchers at the National Eye Institute have developed the first patient-derived stem cell model for studying eye conditions related to oculocutaneous albinism (OCA).
bit.bio has today launched a new product, ioSkeletal Myocytes.
Scientists developed a new screening method that tests the effectiveness of therapeutic molecules developed to “glue” proteins together in the body.
The drug diABZI -- which activates the body's innate immune response -- was highly effective in preventing severe COVID-19 in mice that were infected with SARS-CoV-2,
Researchers at the National Institutes of Health (NIH) have devised a four-part small-molecule cocktail that can protect stem cells called induced pluripotent stem cells (iPSCs) from stress and maintain normal stem cell structure and function.
Researchers at the University of California, Davis, have created a genetically encoded sensor for detecting hallucinogenic substances.
Researchers from the National Institutes of Health have identified and tested a drug combination that exploits a weakness in small cell lung cancer (SCLC), an aggressive, dangerous cancer.
On the basis of a license agreement with the German Center for Neurodegenerative Diseases (DZNE) and the Leibniz Institute of Polymer Research Dresden (IPF), the Dresden-based start-up "Neuron-D GmbH" is developing a high-throughput system for testing drug candidates to treat neurodegenerative diseases.
Assessing a drug compound by its activity, not simply its structure, is a new approach that could speed the search for COVID-19 therapies and reveal more potential therapies for other diseases.
Nuclear magnetic resonance (NMR) is an important tool in drug research, since it can quantify and spatially resolve binding of drugs to pathogens. So far, however, NMR has lacked the sensitivity and throughput to scan large libraries of drug candidates.
Researchers at Linköping University, Sweden, have discovered a new mechanism by which substances can open a certain type of ion channel and in this way regulate nerve impulses.
In their quest to find new drugs to treat deadly diseases, scientists study millions of molecules at high speed at the same time. Often it is enzymes that are investigated as targets in these 'high-throughput' screenings.
A new antiviral drug that is effective against a broad range of human pathogens in the paramyxovirus family, such as the human parainfluenzaviruses and measles virus, has been discovered by researchers in the Institute for Biomedical Sciences at Georgia State University.
Scientists have created a human cell “membrane on a chip” that enables tracking of the interaction of drugs and infectious agents with the human cells.
Genetic engineering of bacteria has transformed contemporary medicine, from bacterial-based insulin to a deeper insight into infectious diseases.
McMaster University researchers have discovered a combination punch to treat drug-resistant infections that is showing promise based on testing in mice.
A group of scientists has developed a fast and cost-effective method of detecting and identifying bioactive compounds in samples such as plant extracts.